You have 9 free searches left this month | for more free features.

ibrutinib

Showing 26 - 50 of 220

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Lymphoma, Non-Hodgkin Lymphoma, DLBCL Trial run by the National Cancer Institute (NCI) (Venetoclax, Ibrutinib, Prednisone)

Recruiting
  • Lymphoma
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 20, 2022

Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in Houston (drug,

Active, not recruiting
  • Prolymphocytic Leukemia
  • +2 more
  • Ibrutinib
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 7, 2022

Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell Trial in Whittier (Pirtobrutinib, Ibrutinib)

Recruiting
  • Chronic Lymphocytic Leukemia
  • +3 more
  • Whittier, California
    Innovative Clinical Research Institute
Aug 8, 2022

Mantle-Cell Lymphoma Trial in United States (Ixazomib, Ibrutinib)

Active, not recruiting
  • Mantle-Cell Lymphoma
  • Atlanta, Georgia
  • +13 more
Nov 17, 2022

Waldenstrom Macroglobulinemia Trial in Japan (Ibrutinib, Rituximab)

Active, not recruiting
  • Waldenstrom Macroglobulinemia
  • Chiba, Japan
  • +8 more
Jan 27, 2023

Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma Trial in

Recruiting
  • Ann Arbor Stage II Follicular Lymphoma
  • +5 more
  • Ibrutinib
  • +2 more
  • Fresno, California
  • +2 more
Jan 24, 2023

Colon Cancer, Colorectal Cancer, Colorectal Carcinoma Trial in Tampa (Pembrolizumab, Ibrutinib)

Completed
  • Colon Cancer
  • +3 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Jun 1, 2022

Leukemia, Lymphocytic, Chronic Trial in Germany (ibrutinib, obinutuzumab, venetoclax)

Completed
  • Leukemia, Lymphocytic, Chronic
  • ibrutinib
  • +2 more
  • Dresden, Germany
  • +10 more
Jan 13, 2023

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin Trial in Worldwide (JNJ-67856633, Ibrutinib)

Active, not recruiting
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Lymphoma, Non-Hodgkin
  • Copenhagen, Denmark
  • +9 more
Jan 27, 2023

Waldenstrom Macroglobulinemia, MYD88 Gene Mutation Trial in Boston (IBRUTINIB, Venetoclax)

Active, not recruiting
  • Waldenstrom Macroglobulinemia
  • MYD88 Gene Mutation
  • Boston, Massachusetts
  • +1 more
Apr 1, 2022

Refractory Follicular Lymphoma, Relapsed Follicular Lymphoma Trial in Washington, Hackensack, Seattle (Ibrutinib, Venetoclax)

Recruiting
  • Refractory Follicular Lymphoma
  • Relapsed Follicular Lymphoma
  • Washington, District of Columbia
  • +2 more
Jul 6, 2022

Waldenstrom Macroglobulinemia Trial in Austria, Germany, Greece (Carfilzomib + Ibrutinib, Ibrutinib)

Recruiting
  • Waldenstrom Macroglobulinemia
  • Carfilzomib + Ibrutinib
  • Ibrutinib
  • Salzburg, Austria
  • +16 more
Mar 11, 2022

Relapsed/Refractory Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Leukemia Trial in Switzerland (Ibrutinib,

Active, not recruiting
  • Relapsed/Refractory Chronic Lymphocytic Leukemia
  • +2 more
  • Aarau, Switzerland
  • +10 more
Mar 10, 2022

Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma Trial in United States (Buparlisib, Ibrutinib)

Completed
  • Lymphoma
  • +3 more
  • Basking Ridge, New Jersey
  • +5 more
Oct 7, 2022

Hematopoietic and Lymphoid Cell Tumor, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in

Not yet recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +5 more
  • Ibrutinib
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 10, 2022

Chronic Lymphocytic Leukemia (CLL) Trial (Venetoclax, Rituximab, Ibrutinib)

Not yet recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • (no location specified)
Apr 2, 2022

Chronic Lymphocytic Leukemia Trial in Boston, Hackensack, New York (Ublituximab, Umbralisib, Ibrutinib)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Boston, Massachusetts
  • +2 more
Aug 19, 2022

Small Lymphocytic Leukemia (SLL), Chronic Lymphocytic Leukemia (CLL) Trial run by the NHLBI (Duvelisib, Ibrutinib)

Terminated
  • Small Lymphocytic Leukemia (SLL)
  • Chronic Lymphocytic Leukemia (CLL)
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 15, 2022

Lymphoma, Non-Hodgkin Lymphoma, DLBCL Trial run by the NCI (obinutuzumab, prednisone, Revlimid)

Recruiting
  • Lymphoma
  • +3 more
  • obinutuzumab
  • +5 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jul 6, 2022

Asymptomatic COVID-19 Infection Laboratory-Confirmed, B-Cell Tumor, Chronic Lymphocytic Leukemia Trial in Rochester (Ibrutinib,

Withdrawn
  • Asymptomatic COVID-19 Infection Laboratory-Confirmed
  • +8 more
  • Ibrutinib
  • Quality-of-Life Assessment
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Aug 2, 2022

Relapsed DLBCL, Refractory DLBCL Trial in Hackensack (ABT-199, Ibrutinib, Rituximab)

Active, not recruiting
  • Relapsed Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Hackensack, New Jersey
    John Theurer Cancer Center at Hackensack University Medical Cent
Oct 7, 2022

Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome Trial in United

Completed
  • Chronic Myelomonocytic Leukemia
  • +4 more
  • Los Angeles, California
  • +4 more
Oct 5, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial run by the NHLBI (Ibrutinib, Fludarabine)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Mar 1, 2022

Chronic Lymphocytic Leukemia Trial in Columbus (biological, drug, other)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Daratumumab
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 24, 2022

Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia Trial in

Active, not recruiting
  • Stage I Chronic Lymphocytic Leukemia
  • +3 more
  • Ibrutinib
  • Laboratory Biomarker Analysis
  • Jacksonville, Florida
    Mayo Clinic in Florida
Mar 24, 2022